See the DrugPatentWatch profile for viberzi
Viberzi is not an opioid. It is a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults [1]. The active ingredient in Viberzi is eluxadoline [2].
How does Viberzi work?
Eluxadoline acts as a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist, and a kappa-opioid receptor agonist. It works locally in the gut by reducing the contractions and secretions of the intestine, which helps to alleviate abdominal pain and diarrhea associated with IBS-D [3].
Can Viberzi be habit-forming?
While Viberzi affects opioid receptors, it is not classified as an opioid and does not have the same potential for abuse and addiction as traditional opioid pain medications [1][3]. However, there is a risk of pancreatitis and sphincter of Oddi dysfunction, particularly in patients who have had their gallbladder removed [4].
What are the potential side effects of Viberzi?
Common side effects of Viberzi include constipation, nausea, abdominal pain, and upper respiratory tract infection [3]. Serious side effects can occur, including pancreatitis and sphincter of Oddi dysfunction, especially in patients without a gallbladder [4].
When does Viberzi's patent expire?
Information regarding the specific patent expiry dates for Viberzi can be found through resources like DrugPatentWatch.com [5]. These patents are crucial for determining when generic versions of the medication may become available.
Who makes Viberzi?
Viberzi is manufactured by AbbVie [2].